Legend Biotech CORP

Peter Salovey, a Director of Legend Biotech Corp, received 28,330 shares of common stock on September 24, 2026.

Tomas J. Heyman, a Director of Legend Biotech Corp, received 20,986 shares of common stock on September 24, 2026.

Li Mao, a Director of Legend Biotech Corp, received 20,986 shares of common stock on September 24, 2026.

Patrick John Casey, a Director of Legend Biotech Corp, received 20,986 shares of common stock on September 24, 2026.

Darren Xiaohui Ji, a Director of Legend Biotech Corp, received 28,330 shares of common stock on September 24, 2026.

Corazon (Corsee) D. Sanders, a Director of Legend Biotech Corp, received 20,986 shares of common stock on September 24, 2026.

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 15.0% of Legend Biotech Corp.'s common stock as of June 30, 2026.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a combined beneficial ownership of 13.1% in Legend Biotech Corp's Ordinary Shares as of December 31, 2025.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 15.0% of Legend Biotech Corp's common stock, totaling over 55 million shares.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 13.9% in Legend Biotech Corp, holding over 51 million common shares as of June 30, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a combined beneficial ownership of 10.9% in Legend Biotech Corp, totaling over 40 million shares.

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, disclosing a 3.7% beneficial ownership stake in Legend Biotech Corp-ADR as of December 31, 2024.